白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2014年
5期
291-293
,共3页
非特异性外周T细胞淋巴瘤%老年人%依托泊苷%泼尼松%药物疗法,联合
非特異性外週T細胞淋巴瘤%老年人%依託泊苷%潑尼鬆%藥物療法,聯閤
비특이성외주T세포림파류%노년인%의탁박감%발니송%약물요법,연합
Unspecific peripheral T-cell lymphoma%Elderly%Etoposide%Prednisone%Drug therapy,combination
目的 探讨持续口服依托泊苷联合泼尼松(EtoP)方案与CHOP方案治疗老年人非特异性外周T细胞淋巴瘤(PTCL-U)的疗效和患者不良反应.方法 23例经病理确诊的老年PTCL-U患者,采用抽签法随机分为EtoP组(12例)与CHOP组(11例),采用Log-rank检验和x2检验对两组的疗效及不良反应进行比较.结果 EtoP组总有效率(RR)为66.67％(8/12),CHOP组为63.64％(7/11),两组差异无统计学意义(x2=0.023,P=0.879).EtoP组无进展生存期(PFS)为7.55个月,总生存期(OS)为15.02个月;CHOP组PFS为4.38个月,OS为12.26个月,两组PFS差异有统计学意义(x2=23.000,P=0.011),OS差异无统计学意义(x2=14.985,P=0.597).两组主要不良反应为血液学毒性和消化道反应.其中EtoP组无Ⅲ～Ⅳ度不良反应发生;CHOP组Ⅲ～Ⅳ度血液学毒性发生率为36.36％,Ⅲ～Ⅳ度消化道反应发生率为27.27％.结论 对于老年人PTCL-U,EtoP方案疗效略优于CHOP方案,不良反应发生率低于CHOP方案,耐受性良好,应用方便且费用低,值得推广.
目的 探討持續口服依託泊苷聯閤潑尼鬆(EtoP)方案與CHOP方案治療老年人非特異性外週T細胞淋巴瘤(PTCL-U)的療效和患者不良反應.方法 23例經病理確診的老年PTCL-U患者,採用抽籤法隨機分為EtoP組(12例)與CHOP組(11例),採用Log-rank檢驗和x2檢驗對兩組的療效及不良反應進行比較.結果 EtoP組總有效率(RR)為66.67％(8/12),CHOP組為63.64％(7/11),兩組差異無統計學意義(x2=0.023,P=0.879).EtoP組無進展生存期(PFS)為7.55箇月,總生存期(OS)為15.02箇月;CHOP組PFS為4.38箇月,OS為12.26箇月,兩組PFS差異有統計學意義(x2=23.000,P=0.011),OS差異無統計學意義(x2=14.985,P=0.597).兩組主要不良反應為血液學毒性和消化道反應.其中EtoP組無Ⅲ～Ⅳ度不良反應髮生;CHOP組Ⅲ～Ⅳ度血液學毒性髮生率為36.36％,Ⅲ～Ⅳ度消化道反應髮生率為27.27％.結論 對于老年人PTCL-U,EtoP方案療效略優于CHOP方案,不良反應髮生率低于CHOP方案,耐受性良好,應用方便且費用低,值得推廣.
목적 탐토지속구복의탁박감연합발니송(EtoP)방안여CHOP방안치료노년인비특이성외주T세포림파류(PTCL-U)적료효화환자불량반응.방법 23례경병리학진적노년PTCL-U환자,채용추첨법수궤분위EtoP조(12례)여CHOP조(11례),채용Log-rank검험화x2검험대량조적료효급불량반응진행비교.결과 EtoP조총유효솔(RR)위66.67％(8/12),CHOP조위63.64％(7/11),량조차이무통계학의의(x2=0.023,P=0.879).EtoP조무진전생존기(PFS)위7.55개월,총생존기(OS)위15.02개월;CHOP조PFS위4.38개월,OS위12.26개월,량조PFS차이유통계학의의(x2=23.000,P=0.011),OS차이무통계학의의(x2=14.985,P=0.597).량조주요불량반응위혈액학독성화소화도반응.기중EtoP조무Ⅲ～Ⅳ도불량반응발생;CHOP조Ⅲ～Ⅳ도혈액학독성발생솔위36.36％,Ⅲ～Ⅳ도소화도반응발생솔위27.27％.결론 대우노년인PTCL-U,EtoP방안료효략우우CHOP방안,불량반응발생솔저우CHOP방안,내수성량호,응용방편차비용저,치득추엄.
Objective To investigate the efficacy and toxicity of etoposide combined with prednisone (EtoP regimen) for elderly patients with unspecific peripheral T-cell lymphoma (PTCL-U) compared with the CHOP regimen.Methods 23 elderly PTCL-U patients were randomly assigned to EtoP group (n =12) or CHOP group (n =11).The curative effects and the adverse reactions were analyzed and compared between the two groups by Log-rank test and x2 test.Results The overall response (OR) rate was 66.67 ％ (8/12) in EtoP group and 63.64 ％ (7/11) in CHOP group.There was no statistically significant difference between the two groups(x2 =0.023,P =0.879).The progression-free survival (PFS) was 7.55 months in EtoP group and 4.38 months in CHOP group,statistically significant difference were observed between the two groups (x2 =23.000,P =0.011).The overall survival (OS) was 15.02 months in EtoP group and 12.26 months in CHOP group,no statistically significant difference was observed between the two groups (x 2 =14.985,P =0.597).The main side effects were bone marrow depression and digestive tract toxicity,no hematology toxicity and digestive tract toxicity of grade Ⅲ-Ⅳ occurred in EtoP group.Of those in CHOP group were 36.36 ％ and 27.27 ％.Conclusion For elderly PTCL-U patients,EtoP regimen is an effective and well tolerated therapeutic schedule.
